175 tracked 13F filers disclose a position in ELVN as of the latest SEC 13F filings, a combined $2.7B in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | $312.0M | 8.0M | —Held | Q1 2026 | |
| 2 | FMR LLC | $267.7M | 6.8M | ▼−3.9% Reduced · −278K sh | Q1 2026 | |
| 3 | Polar Capital Holdings Plc | $326.4M | 6.4M | ▲+27% Added · +1.4M sh | Q2 2026 | |
| 4 | BlackRock, Inc. | $144.4M | 3.7M | ▲+2.0% Added · +71K sh | Q1 2026 | |
| 5 | Commodore Capital LP | $128.4M | 3.3M | ▼−30% Reduced · −1.4M sh | Q1 2026 | |
| 6 | Vestal Point Capital, LP | $127.4M | 3.3M | ▼−15% Reduced · −580K sh | Q1 2026 | |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $85.0M | 2.2M | →First observed position No prior filed position | Q1 2026 | |
| 8 | Fairmount Funds Management LLC | $94.2M | 1.9M | —Held | Q2 2026 | |
| 9 | Siren, L.L.C. | $90.1M | 1.8M | ▲+138% Added · +1.0M sh | Q2 2026 | |
| 10 | CITADEL ADVISORS LLC | $68.4M | 1.7M | ▲+22% Added · +320K sh | Q1 2026 | |
| 11 | Venrock Adviser, LLC | $67.7M | 1.7M | ▼−46% Reduced · −1.5M sh | Q1 2026 | |
| 12 | Bellevue Group AG | $75.6M | 1.5M | ▼−36% Reduced · −831K sh | Q2 2026 | |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | $71.4M | 1.4M | ▲+32% Added · +341K sh | Q2 2026 | |
| 14 | STATE STREET CORP | $61.6M | 1.2M | ▲+11% Added · +123K sh | Q2 2026 | |
| 15 | Novo Holdings A/S | $50.8M | 1.0M | ▼−22% Reduced · −280K sh | Q2 2026 | |
| 16 | First Turn Management, LLC | $48.4M | 954K | ▲+53% Added · +331K sh | Q2 2026 | |
| 17 | Pictet Asset Management Holding SA | $36.4M | 930K | ▼−29% Reduced · −374K sh | Q1 2026 | |
| 18 | Candriam S.C.A. | $45.9M | 906K | ▲+52% Added · +312K sh | Q2 2026 | |
| 19 | BAKER BROS. ADVISORS LP | $35.5M | 905K | ▲+234% Added · +634K sh | Q1 2026 | |
| 20 | ALLIANCEBERNSTEIN L.P. | Withheld | 772K | ▲21× Added · +735K sh | Q1 2026 | |
| 21 | DIMENSIONAL FUND ADVISORS LP | $26.7M | 682K | ▲+71% Added · +283K sh | Q1 2026 | |
| 22 | Affinity Asset Advisors, LLC | $23.0M | 587K | ▲New +587K sh | Q1 2026 | |
| 23 | Logos Global Management LP | $21.2M | 540K | ▲+59% Added · +200K sh | Q1 2026 | |
| 24 | MORGAN STANLEY | $20.3M | 519K | ▲+26% Added · +107K sh | Q1 2026 | |
| 25 | SILVERARC CAPITAL MANAGEMENT, LLC | $24.8M | 489K | ▲Added Added · +489K sh | Q2 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 21 funds opened a new position in ELVN and 26 added to an existing one, while 13 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| REVOLUTION MEDICINES INCRVMD | 84 funds | $4.9B |
| XENON PHARMACEUTICALS INCXENE | 83 funds | $1.9B |
| COGENT BIOSCIENCES INCCOGT | 82 funds | $1.9B |
| NVIDIA CORPNVDA | 81 funds | $280.9B |
| AMAZON.COM INCAMZN | 81 funds | $136.4B |
| INSMED INCINSM | 81 funds | $5.8B |
| ELI LILLY & COLLY | 79 funds | $59.5B |
| CYTOKINETICS INCCYTK | 79 funds | $1.5B |
| MICRON TECHNOLOGY INCMU | 78 funds | $24.1B |
| MICROSOFT CORPMSFT | 76 funds | $185.3B |
| META PLATFORMS INC-CLASS AMETA | 76 funds | $80.9B |
| UNITEDHEALTH GROUP INCUNH | 76 funds | $19.3B |
Ranked by how many of ELVN's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell (S) | 1K | $65K |
| Aug 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell (S) | 4K | $228K |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 1K | $82K |
| Aug 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 5K | $270K |
| Aug 4, 2026 | Derynck Mika K | Director | Sell (S) | 159K | $9.6M |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 324 | $16K |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 369 | $19K |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 3K | $134K |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 3K | $141K |
| Jul 17, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell (S) | 123 | $7K |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell (S) | 231 | $12K |
| Jul 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell (S) | 459 | $24K |
Connected entities for ELVN
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ELVN/capital-change-brief"
Use Arkolith's capital_change_brief for ELVN. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ELVN. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.